/https://i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2026/L/l/YBEWdIRZqzcZZkine1tQ/foto-g1-14-.png)
/https://i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2026/M/Z/r8nyUMRF6mh2MSyYQoPg/palmer.jpeg)
/https://i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2026/R/m/vq7ATLRICAr27GyFPUpw/whatsapp-image-2026-08-11-at-21.22.19.jpeg)
/https://i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2026/A/A/5VVQl7SJ2guyRQlE6bAQ/whatsapp-image-2026-09-22-at-4.15.56-pm.jpeg)
/https://i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2022/t/X/cCsDzFTCWfBqd51zoPlw/gettyimages-1239846199.jpg)
Além do emagrecimento: canetas entram na prevenção cardiovascular
Por Pedro Julien Salvarani. Novas indicações de semaglutida e tirzepatida levam medicamentos conhecidos pela perda de peso ao debate sobre prevenção de infarto, AVC e acesso no SUS.
/https://i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2026/D/t/BmQsrqSmuT5dh9hS5ORg/autocuratela1.jpg)